financetom
Business
financetom
/
Business
/
--BorgWarner Keeps Quarterly Dividend at $0.17 a Share, Payable March 16 to Shareholders of Record as of March 2
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--BorgWarner Keeps Quarterly Dividend at $0.17 a Share, Payable March 16 to Shareholders of Record as of March 2
Mar 11, 2026 3:09 AM

02:36 PM EST, 02/05/2026 (MT Newswires) --

Price: 50.50, Change: +0.01, Percent Change: +0.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
-- Vecima Networks Brief: Keeps Buy But Price Target Lowered To C$23 From $28 As Sees Q3 Revs Outlook
-- Vecima Networks Brief: Keeps Buy But Price Target Lowered To C$23 From $28 As Sees Q3 Revs Outlook "Flat To Slightly Higher" Vs Q2
Feb 10, 2025
10:27 AM EST, 02/10/2025 (MT Newswires) -- Price: 12.56, Change: +0.21, Percent Change: +1.70 ...
Rockwell Automation Defies Q1 Sales Decline With Cost Discipline And Strong Cash Flow; Stock Jumps
Rockwell Automation Defies Q1 Sales Decline With Cost Discipline And Strong Cash Flow; Stock Jumps
Feb 10, 2025
Rockwell Automation, Inc. ( ROK ) shares surged after the company reported better-than-expected first-quarter results. Sales fell 8.4% year over year and slid 7.6% organically to $1.881 billion, in line with the consensus of $1.881 billion. Segment Details: Intelligent Devices sales declined 13.1% to $806 million, Software & Control fell 12.4% to $529 million, and Lifecycle Services rose 5% to...
INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe
INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe
Feb 10, 2025
10:25 AM EST, 02/10/2025 (MT Newswires) -- INmune Bio ( INMB ) said Monday it is planning to submit a biologics license application to the US Food and Drug Administration, as well as marketing authorization applications in the UK and the European Union seeking approval of CORDStrom to treat recessive dystrophic epidermolysis bullosa in pediatric patients. According to the company,...
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
Feb 10, 2025
On Saturday, 4D Molecular Therapeutics ( FDMT ) announced initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM trial of 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population. Additional data were provided on the durability of aflibercept expression for up to two years. Topline 52-Week Efficacy Results for 4D-150 3E10 vg/eye (Planned...
Copyright 2023-2026 - www.financetom.com All Rights Reserved